Glaxo Takes Aim at Covid-19 in $250 Million Pact With Vir
(Bloomberg) -- U.K. pharmaceutical giant GlaxoSmithKline Plc is joining dozens of companies in the hunt for coronavirus therapies, signing a partnership with Vir Biotechnology Inc. and agreeing to invest $250 million in the U.S. company.
Glaxo and Vir will work together to find experimental antibodies to treat or prevent Covid-19, the illness caused by the coronavirus, the British drugmaker said on Monday. The companies plan to move two candidates straight into mid-stage trials in three to five months, subject to regulatory approval, Glaxo said.
“It is becoming increasingly clear that multiple therapeutic approaches, used in combination or in sequence, will be necessary to stop this coronavirus pandemic,” Vir Chief Executive Officer George Scangos said in the statement. “It is likely that the current coronavirus outbreak will not be the last.”
Glaxo and Vir will also combine their experience with Crispr, the gene-editing technology, to identify compounds. They will look at potential vaccines for Covid-19, as well as treatments and shots for other coronaviruses. Any approved treatments would still be many months, if not years, away. The partnership will be the first time the two have officially worked together.
The pact is the latest investment Glaxo is making in the fight against the coronavirus pandemic. The company formed a research partnership on a potential vaccine with Clover Biopharmaceuticals, a Chinese company, in February, and is also working with AstraZeneca Plc and the U.K. government to set up a lab to explore new ways of testing for the virus to help overcome shortages of diagnostic materials, a person familiar with the plans said.
The equity investment is priced at $37.73 a share, GSK said. Shares of the San Francisco-based company, which closed at $29 on Friday, surged by as much as 38% on Monday.
The investment comes two days before the end of selling restrictions related to Vir's initial public offering. The April 8 lockup expiration marks the first opportunity for insiders to sell their shares since Vir went public in October at $20.
Working with the Coalition for Epidemic Preparedness Innovations, Glaxo agreed earlier this year to bring its technology to the race for a vaccine. That effort will rely on Glaxo's adjuvant system, designed to enhance the body's immune response and create stronger and longer lasting protection.
Almost 5,000 people have died from Covid-19 in the U.K. so far and the peak of the outbreak is likely to hit in the next 7-10 days, according to government advisers and scientists. Prime Minister Boris Johnson was hospitalized on Sunday as a precaution after failing to shake off the virus and its symptoms for 10 days. Many of Britain's neighbors are showing signs they may have reached peaks, with Spain, Italy and France all reporting a slowdown in deaths.
More than 100 experimental and off-the-shelf therapies are being evaluated to treat the coronavirus, either formally or informally. A number of them have grabbed headlines, including hydroxychloroquine, the antimalarial touted as a treatment by President Donald Trump, and remdesivir, an experimental drug from Gilead Sciences Inc.
©2020 Bloomberg L.P.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.